EXICURE, INC.
Business
Exicure, Inc. is a publicly-traded biotechnology company that historically developed nucleic acid therapies but ceased R&D in September 2022 and has since divested its core intellectual property and assets. The company is currently pursuing strategic alternatives including acquisitions, partnerships, and licensing arrangements to create shareholder value. Recent activities include acquiring GPCR Therapeutics USA to develop small-molecule oncology therapeutics combining GPC-100 and propranolol for stem-cell mobilization in multiple myeloma, with clinical trials ongoing.
Summary from 10-K filed 2026-03-25
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 500,000 | 0 | — | — | |
| Total revenue | 0 | 500,000 | 0 | 29 | −483,000 | |
| Research and development expense | 3 | 0 | 1 | 20 | 49 | |
| General and administrative expense | 7 | 5 | 12 | 11 | 13 | |
| Litigation legal expense | 0 | 2 | 938,000 | — | — | |
| Right-of-use asset impairment loss | 0 | 6 | 0 | — | — | |
| Loss from sale of property and equipment | 90,000 | 0 | — | — | — | |
| Gain on early lease termination | −6 | 0 | — | — | — | |
| Total operating expenses | 4 | 13 | 15 | 31 | 62 | |
| Operating loss | −4 | −12 | −15 | −2 | −63 | |
| Dividend income | 107,000 | 5,000 | 52,000 | 78,000 | 8,000 | |
| Interest income | 29,000 | 8,000 | 32,000 | 15,000 | 141,000 | |
| Interest expense | −1,000 | −18,000 | 0 | — | — | |
| Gain on settlement of accounts payables | 346,000 | 407,000 | 0 | — | — | |
| Change in fair value of contingent liability | −2 | 0 | — | — | — | |
| Other income (expense), net | −275,000 | 2 | −2,000 | −40,000 | −11,000 | |
| Total other income (expense), net | −1 | 3 | −2 | −542,000 | −2 | |
| Net loss before provision for income taxes | −6 | −10 | −17 | −2 | −64 | |
| Provision (benefit) for income taxes | −634,000 | 8,000 | 0 | 209,000 | 0 | |
| Net loss | −5 | −10 | −17 | −3 | −64 | |
| Basic loss per common share (in USD per share) | −0.79 | −4.75 | −10.55 | −0.56 | −21.7 | |
| Diluted loss per common share (in USD per share) | −0.79 | −4.75 | −10.55 | −0.56 | −21.7 | |
| Weighted-average basic common shares outstanding (in shares) | 6 | 2 | 2 | 5 | 3 | |
| Weighted-average diluted common shares outstanding (in shares) | 6 | 2 | 2 | 5 | 3 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash, cash equivalents and restricted cash | 4 | 13 | 816,000 | — | — | |
| Other receivable | 58,000 | 521,000 | 15,000 | 0 | — | |
| Prepaid expenses and other current assets | 820,000 | 644,000 | 1 | 1 | 5 | |
| Total current assets | 5 | 14 | 2 | 10 | 44 | |
| Other noncurrent assets | 928,000 | 1 | 3 | 3 | 9 | |
| Property and equipment, net | 306,000 | 26,000 | 54,000 | 3 | 4 | |
| Goodwill | 4 | 0 | — | — | — | |
| Intangible asset | 4 | 0 | — | — | — | |
| Total assets | 14 | 15 | 12 | 23 | 65 | |
| Accounts payable | 2 | 1 | 2 | 361,000 | 3 | |
| Accrued expenses and other current liabilities | 2 | 2 | 879,000 | 1 | 6 | |
| Total current liabilities | 4 | 3 | 3 | 2 | 34 | |
| Contingent consideration | 6 | 0 | — | — | — | |
| Deferred tax liability | 423,000 | 0 | — | — | — | |
| Lease liability, noncurrent | 0 | 5 | 6 | 7 | 7 | |
| Total liabilities | 10 | 8 | 9 | 8 | 54 | |
| Commitments and Contingencies (Note 15) | — | — | — | — | — | |
| Preferred stock, $0.0001 par value per share; 10,000,000 shares authorized, no shares issued and outstanding, December 31, 2025 and December 31, 2024 | 0 | 0 | 0 | 0 | 0 | |
| Common stock, $0.0001 par value per share; 200,000,000 shares authorized, 6,373,893 issued and outstanding, December 31, 2025; 6,026,841 issued and outstanding, December 31, 2024 | 1,000 | 1,000 | 0 | 0 | 0 | |
| Additional paid-in capital | 208 | 206 | 193 | 188 | 181 | |
| Accumulated other comprehensive loss | −2,000 | 0 | 0 | 0 | −2,000 | |
| Accumulated deficit | −204 | −199 | −190 | −173 | −170 | |
| Total stockholders equity | 4 | 7 | 3 | 15 | 11 | |
| Total liabilities and stockholders equity | 14 | 15 | 12 | 23 | 65 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation and amortization | 242,000 | 28,000 | 634,000 | 1 | 1 | |
| Amortization of right-of-use asset | 218,000 | 796,000 | 741,000 | 693,000 | 656,000 | |
| Equity-based compensation | 2,000 | 22,000 | 1 | 1 | 3 | |
| Loss on disposal/sale of subsidiary | 98,000 | 0 | — | — | — | |
| Income tax benefit | −634,000 | 0 | — | — | — | |
| Accounts receivable | 1 | −506,000 | 0 | 0 | 11,000 | |
| Prepaid expenses and other current assets | 39,000 | 977,000 | 733,000 | 3 | −295,000 | |
| Other noncurrent assets | 198,000 | 0 | 38,000 | −2 | 68,000 | |
| Accounts payable | 177,000 | −193,000 | 1 | −3 | 2 | |
| Accrued expenses | −614,000 | 1 | −399,000 | −5 | 3 | |
| Other liabilities | 0 | −827,000 | −728,000 | −637,000 | −555,000 | |
| Net cash used in operating activities | −9 | −3 | −10 | −36 | −35 | |
| Capital expenditures | −1,000 | 0 | 0 | −10,000 | −968,000 | |
| Proceeds from sale of fixed assets | 42,000 | 0 | 922,000 | 205,000 | 0 | |
| Acquisition of GPCR Therapeutics USA Inc. | −2 | 0 | −2 | −1 | −6 | |
| Proceeds from sale of subsidiary | 474,000 | 0 | — | — | — | |
| Cash removed from the sale of KCC | −232,000 | — | — | — | — | |
| Net cash used in by investing activities | −2 | 0 | −1 | 5 | 43 | |
| Proceeds from sale of common stock | 2 | 12 | 5 | 5 | 11 | |
| Proceeds from short term debt | 0 | 1 | 0 | — | — | |
| Net cash provided by financing activities | 2 | 13 | 4 | −3 | 1 | |
| Net (decrease) in cash, cash equivalents, and restricted cash | −9 | 10 | −8 | −34 | 9 |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is EXICURE, INC.'s CIK number?
EXICURE, INC.'s SEC CIK number is 0001698530 (1698530). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find EXICURE, INC.'s SEC filings?
All of EXICURE, INC.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did EXICURE, INC. last report earnings?
EXICURE, INC. (XCUR) most recently filed an earnings 8-K with the SEC on Mar 25, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001698530-26-000026). This is EXICURE, INC.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is EXICURE, INC.'s most recent earnings 8-K?
EXICURE, INC.'s latest earnings 8-K (Item 2.02) was filed Mar 25, 2026 under accession 0001698530-26-000026. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View EXICURE, INC.'s latest earnings 8-K →
Look up any company's CIK number →